There's something powerful about backing a great business and simply holding on. Not for six months. Not until the next earnings update. But for a full decade — riding the waves, ignoring the noise, and letting compounding do its thing.

The ASX may not have as many high-flying tech names as Wall Street, but it certainly has its fair share of world-class businesses. The kind that are growing globally, delivering strong earnings, and quietly building shareholder wealth year after year.

Here are three ASX 200 stocks that analysts rate as buys that I'd feel confident holding all the way through to 2035.

Life360 Inc. (ASX: 360)

Life360 is a location technology company known for its eponymous family safety app. It is gaining serious traction, with its user base reaching around 80 million.

The business model is sticky, the monetisation levers are only just beginning to turn, and management has its eyes on expanding into other complementary areas, which could bring valuation upside.

With a large addressable market, expanding product suite, and strong user engagement, Life360 could look like a very different business in a decade. And at current levels, long-term investors may be getting in before the real growth kicks in.

Goldman Sachs has a buy rating and $27.00 price target on its shares.

ResMed Inc. (ASX: RMD)

Another ASX 200 stock that could be a top buy and hold option is ResMed. It is one of the ASX's global healthcare success stories. This medical device company is a leader in sleep disorder treatment, offering devices, masks, and cloud-connected software that support patients across the globe.

Despite recent share price pressure linked to weight-loss drugs (GLP-1s), the company's fundamentals remain incredibly strong. ResMed continues to grow its earnings, expand margins, and generate serious cash flow. In fact, GLP-1s have helped to raise awareness of sleep apnoea, which appears to be expanding its addressable market at a quicker than expected rate.

What makes it a compelling 10-year hold is the sheer scale of the problem it solves. Sleep apnoea is underdiagnosed and growing globally, and ResMed has the brand power, distribution, and tech stack to remain the leader in the space.

Goldman Sachs is also very bullish on ResMed and has a conviction buy rating and $49.00 price target on its shares.

WiseTech Global Ltd (ASX: WTC)

Finally, WiseTech could be a great ASX 200 stock to buy and hold. It has built one of the most dominant software platforms in global logistics. Its CargoWise system is used by some of the largest freight companies in the world to manage customs, compliance, and end-to-end supply chains.

With recurring revenue, huge scalability, and strong customer retention, WiseTech is everything you want in a long-term growth investment.

So, with its shares down sharply from their highs, now could be an opportune time to invest. Macquarie certainly thinks so. It recently put an outperform rating and $152.70 price target on its shares.